These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Androgen signal transduction and prostatic carcinoma. Klocker H; Culig Z; Kaspar F; Hobisch A; Eberle J; Reissigl A; Bartsch G World J Urol; 1994; 12(2):99-103. PubMed ID: 8087144 [TBL] [Abstract][Full Text] [Related]
5. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Culig Z; Hobisch A; Hittmair A; Peterziel H; Radmayr C; Bartsch G; Cato AC; Klocker H Histol Histopathol; 1997 Jul; 12(3):781-6. PubMed ID: 9225161 [TBL] [Abstract][Full Text] [Related]
6. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791 [TBL] [Abstract][Full Text] [Related]
7. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190 [TBL] [Abstract][Full Text] [Related]
8. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761 [TBL] [Abstract][Full Text] [Related]
15. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
16. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238 [TBL] [Abstract][Full Text] [Related]
17. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977 [TBL] [Abstract][Full Text] [Related]
18. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Miyamoto H; Marwah P; Marwah A; Lardy H; Chang C Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4440-4. PubMed ID: 12672951 [TBL] [Abstract][Full Text] [Related]
19. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Paul R; Breul J Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345 [TBL] [Abstract][Full Text] [Related]
20. The androgen receptor gene and its influence on the development and progression of prostate cancer. Montgomery JS; Price DK; Figg WD J Pathol; 2001 Sep; 195(2):138-46. PubMed ID: 11592091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]